
Dimitrios Farmakis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1611849/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
2	Anticoagulation for atrial fibrillation in active cancer (Review). Oncology Letters, 2022, 23, 124.	0.8	6
3	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867.	1.0	14
4	GuÃa ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	0.6	40
5	Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 1162-1170.	2.9	13
6	Interatrial Block Predicts Lifeâ€Threatening Arrhythmias in Dilated Cardiomyopathy. Journal of the American Heart Association, 2022, 11, .	1.6	4
7	Right ventricular involvement in cancer therapy–related cardiotoxicity: the emerging role of strain echocardiography. Heart Failure Reviews, 2021, 26, 1189-1193.	1.7	20
8	Arrhythmias in cancer: rhythm is gonna get you!. European Journal of Heart Failure, 2021, 23, 154-156.	2.9	8
9	Extracorporeal life support at the emergency department: new insights into the management of acute cardiac care patients. Hellenic Journal of Cardiology, 2021, 62, 46-47.	0.4	0
10	A critical appraisal of the pharmacological management of stable angina. Hellenic Journal of Cardiology, 2021, 62, 135-138.	0.4	1
11	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp> . European Journal of Heart Failure, 2021, 23, 872-881.	2.9	160
12	Association between upâ€ŧitration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 2021, 23, 1170-1181.	2.9	11
13	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
14	Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a nonâ€randomized, openâ€label, proofâ€ofâ€concept study. European Journal of Heart Failure, 2021, 23, 593-597.	2.9	21
15	Anticoagulation for atrial fibrillation in active cancer: what the cardiologists think. European Journal of Preventive Cardiology, 2021, 28, 608-610.	0.8	16
16	Levosimendan in Europe and China: An Appraisal of Evidence and Context. European Cardiology Review, 2021, 16, e42.	0.7	1
17	Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. Journal of Geriatric Cardiology, 2021, 18, 783-795.	0.2	7
18	Quality of Life is Related to Haemodynamics in Precapillary Pulmonary Hypertension. Heart Lung and Circulation, 2020, 29, 142-148.	0.2	11

#	Article	IF	CITATIONS
19	Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy. Cardiovascular Research, 2020, 116, 576-591.	1.8	32
20	Distribution, infrastructure, and expertise of heart failure and cardioâ€oncology clinics in a developing network: temporal evolution and challenges during the coronavirus disease 2019 pandemic. ESC Heart Failure, 2020, 7, 3408-3413.	1.4	6
21	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp> . European lournal of Heart Failure. 2020. 22. 1966-1983.	2.9	184
22	Differential effects of inotropes and inodilators on renal function in acute cardiac care. European Heart Journal Supplements, 2020, 22, D12-D19.	0.0	10
23	Is cardioâ€oncology a rapidly growing field of precision medicine?. European Journal of Heart Failure, 2020, 22, 2310-2313.	2.9	6
24	Focused echocardiography in cardioâ€oncology. Echocardiography, 2020, 37, 1149-1158.	0.3	11
25	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European lournal of Heart Failure. 2020. 22. 2272-2289.	2.9	92
26	Assessing frailty in heart failure. European Journal of Heart Failure, 2020, 22, 2134-2137.	2.9	6
27	therapies: a position statement and new risk assessment tools from the <scp>C</scp> ardioâ€ <scp>O</scp> ncology <scp>S</scp> tudy <scp>G</scp> roup of the <scp>H</scp> eart <scp>F</scp> ailure <scp>A</scp> ssociation of the <scp>E</scp> uropean <scp>S</scp> ociety of <scp>C</scp> ardiology in collaboration with the <scp>I</scp> nternational	2.9	364
28	<scp>C</scp> ardioaeexscp>Oncology <scp>S</scp> ociety. European Journal of Heart Failure, 2020, The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Failure Reviews, 2020, 26, 1345-1358.	1.7	15
29	Sodium–glucose coâ€transporter 2 inhibitors: â€~a tale of two sisters', diabetes and heart failure. European Journal of Heart Failure, 2020, 22, 1259-1262.	2.9	2
30	The changing epidemiology of the ageing thalassaemia populations: A position statement of the Thalassaemia International Federation. European Journal of Haematology, 2020, 105, 16-23.	1.1	35
31	Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 7, 321-323.	1.4	9
32	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 4-22.	0.8	49
33	COVIDâ€19 and thalassaemia: A position statement of the Thalassaemia International Federation. European Journal of Haematology, 2020, 105, 378-386. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position	1.1	31
34	statement on behalf of the <scp>H</scp> eart <scp>F</scp> ailure <scp>A</scp> sociation (<scp>HFA</scp>), the <scp>E</scp> uropean <scp>A</scp> sociation of <scp>C</scp> ardiovascular <scp>I</scp> maging (<scp>EACVI</scp>) and the <scp>Cardioâ€Oncology C</scp> ouncil of the <scp>E</scp> uropean <scp>S</scp> ociety of <scp>C</scp> ardiology (<scp>ESC</scp>). European	2.9	234
35	Journal of Heart Failure, 2020, 22, 1504-1524. How to develop a national heart failure clinics network: a consensus document of the Hellenic Heart Failure Association. ESC Heart Failure, 2020, 7, 15-25.	1.4	10
36	High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. European Heart Journal, 2020, 41, 4050-4056.	1.0	83

#	Article	IF	CITATIONS
37	Cardioâ€oncology services during the <scp>COVID</scp> â€19 pandemic: practical considerations and challenges. European Journal of Heart Failure, 2020, 22, 929-932.	2.9	4
38	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. European Heart Journal, 2020, 41, 1720-1729.	1.0	154
39	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac Failure Review, 2020, 6, e19.	1.2	37
40	Telephone based survey in adults with congenital heart disease during COVID-19 pandemic. Cardiology Journal, 2020, 27, 636-638.	0.5	8
41	Cardiogenic shock in cancer. Heart Failure Reviews, 2019, 24, 997-1004.	1.7	15
42	A look back: the quest for thrombosis in heart failure continues after COMMANDER HF. Cardiovascular Research, 2019, 115, e140-e142.	1.8	4
43	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure—Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. Journal of Clinical Medicine, 2019, 8, 1834.	1.0	14
44	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	0.8	42
45	Cardiovascular complications of metastatic colorectal cancer treatment. Journal of Gastrointestinal Oncology, 2019, 10, 797-806.	0.6	13
46	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	2.9	224
47	Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. European Journal of Heart Failure, 2019, 21, 529-535.	2.9	56
48	Recent advances in cardioâ€oncology: a report from the â€~Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'. ESC Heart Failure, 2019, 6, 1140-1148.	1.4	34
49	Practical Recommendations for the Diagnosis and Medical Management of Stable Angina. Journal of Cardiovascular Pharmacology, 2019, 74, 308-314.	0.8	4
50	Alternative Modes of Exercise Training in Heart Failure With Preserved Ejection Fraction: Is It Time to Give Them Serious Consideration?. Revista Espanola De Cardiologia (English Ed), 2019, 72, 279-281.	0.4	0
51	Modelos alternativos de ejercicios de entrenamiento en la insuficiencia cardiaca con función conservada: ¿es el momento para su implementación?. Revista Espanola De Cardiologia, 2019, 72, 279-281.	0.6	0
52	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. European Journal of Heart Failure, 2018, 20, 879-887.	2.9	138
53	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	2.9	434
54	Anthracyclineâ€induced cardiomyopathy: secrets and lies. European Journal of Heart Failure, 2018, 20, 907-909.	2.9	24

4

#	Article	IF	CITATIONS
55	Renin inhibition in heart failure and diabetes: the real story. European Journal of Heart Failure, 2018, 20, 149-151.	2.9	7
56	Effects of functional electrical stimulation of lower limb muscles on circulating endothelial progenitor cells, CD34+ cells and vascular endothelial growth factorâ€A in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2018, 20, 1162-1163.	2.9	2
5 7	Hypothalamic dysfunction in heart failure: pathogenetic mechanisms and therapeutic implications. Heart Failure Reviews, 2018, 23, 55-61.	1.7	11
58	Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clinical Research in Cardiology, 2018, 107, 76-86.	1.5	15
59	Ups and downs in heart failure: the case of proteomics. European Journal of Heart Failure, 2018, 20, 63-66.	2.9	6
60	Modernâ€day cardioâ€oncology: a report from the â€~Heart Failure and World Congress on Acute Heart Failure 2018'. ESC Heart Failure, 2018, 5, 1083-1091.	1.4	23
61	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	1.0	171
62	Anti-Thrombotic Therapy after Trans-Catheter Aortic Valve Implantation: Time for Refinement. Cardiology, 2018, 141, 66-68.	0.6	1
63	Heart Disease in Patients with Haemoglobinopathies. Thalassemia Reports, 2018, 8, 7480.	0.1	0
64	How to build a cardioâ€oncology service?. European Journal of Heart Failure, 2018, 20, 1732-1734.	2.9	27
65	Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing. Cardiology, 2018, 140, 126-132.	0.6	19
66	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clinical Research in Cardiology, 2017, 106, 444-456.	1.5	8
67	Effect of functional electrical stimulation on cardiovascular outcomes in patients with chronic heart failure. European Journal of Preventive Cardiology, 2017, 24, 833-839.	0.8	11
68	How to Use Beta-Blockers in Heart FailureÂWith Reduced Ejection Fraction and Atrial Fibrillation â^—. Journal of the American College of Cardiology, 2017, 69, 2897-2900.	1.2	10
69	Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clinical Research in Cardiology, 2017, 106, 359-368.	1.5	57
70	Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, andÂmanagement. European Journal of Heart Failure, 2017, 19, 479-489.	2.9	31
71	Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Failure, 2017, 4, 312-318.	1.4	22
72	Percutaneous coronary intervention reduces mortality in myocardial infarction patients with comorbidities: Implications for elderly patients with diabetes or kidney disease. International Journal of Cardiology, 2017, 249, 83-89.	0.8	21

#	Article	IF	CITATIONS
73	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal of Heart Failure, 2017, 19, 9-42.	2.9	920
74	Heart failure registries: how far can we go?. European Journal of Heart Failure, 2016, 18, 626-628.	2.9	8
75	Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. International Journal of Cardiology, 2016, 222, 303-312.	0.8	103
76	Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience. International Journal of Cardiology, 2016, 223, 781-784.	0.8	9
77	Structured discharge instructions for hospitalized heart failure patients to improve guideline implementation and patient outcomes. International Journal of Cardiology, 2016, 220, 143-145.	0.8	3
78	Natriuretic peptides revisited. Journal of Cardiovascular Medicine, 2016, 17, 840-842.	0.6	2
79	Body mass index in acute heart failure: association with clinical profile, therapeutic management and inâ€hospital outcome. European Journal of Heart Failure, 2016, 18, 298-305.	2.9	25
80	Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: feasibility, and clinical and pathogenetic correlates. European Journal of Heart Failure, 2016, 18, 822-829.	2.9	28
81	Diet and Exercise for Obese Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2016, 315, 2618.	3.8	Ο
82	The medical and socioeconomic burden of heart failure: A comparative delineation with cancer. International Journal of Cardiology, 2016, 203, 279-281.	0.8	64
83	Functional electrical stimulation of lower limb muscles as an alternative mode of exercise training in chronic heart failure: practical considerations and proposed algorithm. European Journal of Heart Failure, 2015, 17, 1228-1230.	2.9	19
84	Overcoming the ethnic differences in patients hospitalized for heart failure: is there a need for international harmonization of clinical practice guidelines?. European Journal of Heart Failure, 2015, 17, 755-757.	2.9	5
85	Transient carotid ischemia as a remote conditioning stimulus for myocardial protection in anesthetized rabbits: Insights into intracellular signaling. International Journal of Cardiology, 2015, 184, 140-151.	0.8	14
86	Prognostic value of in-hospital change in cystatin C in patients with acutely decompensated heart failure and renal dysfunction. International Journal of Cardiology, 2015, 182, 74-76.	0.8	15
87	Acute Heart Failure: Epidemiology, Risk Factors, and Prevention. Revista Espanola De Cardiologia (English Ed), 2015, 68, 245-248.	0.4	64
88	Ligands involved in conditioning may enhance the protection afforded by remote ischemia and reperfusion. International Journal of Cardiology, 2015, 190, 273-274.	0.8	2
89	Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Medicine, 2015, 13, 35.	2.3	23
90	Myocardial deformation imaging unmasks subtle left ventricular systolic dysfunction in asymptomatic and treatment-naÃ ⁻ ve HIV patients. Clinical Research in Cardiology, 2015, 104, 975-981.	1.5	14

#	Article	IF	CITATIONS
91	Efficacy and safety of functional electrical stimulation of lower limb muscles in elderly patients with chronic heart failure: A pilot study. European Journal of Preventive Cardiology, 2015, 22, 831-836.	0.8	19
92	In-hospital management of acute heart failure: Practical recommendations and future perspectives. International Journal of Cardiology, 2015, 201, 231-236.	0.8	31
93	Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital. International Journal of Cardiology, 2015, 180, 46-49.	0.8	35
94	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. European Heart Journal, 2014, 35, 1041-1050.	1.0	90
95	Insights Into Onco-Cardiology. Journal of the American College of Cardiology, 2014, 63, 945-953.	1.2	295
96	Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. Journal of Molecular and Cellular Cardiology, 2014, 69, 4-16.	0.9	98
97	Renal dysfunction and heart failure: things are seldom what they seem. European Heart Journal, 2014, 35, 416-418.	1.0	58
98	International differences in acute coronary syndrome patients' baseline characteristics, clinical management and outcomes in Western Europe: the EURHOBOP study. Heart, 2014, 100, 1201-1207.	1.2	56
99	Selenium contributes to myocardial injury and cardiac remodeling in heart failure. International Journal of Cardiology, 2014, 176, 272-273.	0.8	18
100	Cardio–reno–hepatic interactions in acute heart failure: The role of γ-glutamyl transferase. International Journal of Cardiology, 2014, 173, 556-557.	0.8	7
101	Novel Biomarkers in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 63, 1654-1656.	1.2	7
102	Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity. Clinical Research in Cardiology, 2014, 103, 733-741.	1.5	32
103	Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot survey. European Heart Journal: Acute Cardiovascular Care, 2014, 204887261452701.	0.4	20
104	Anticoagulant therapy is prescribed less often in paroxysmal atrial fibrillation regardless of thromboembolic risk: Results from the Registry of Atrial Fibrillation To Investigate New Guidelines (RAFTING). International Journal of Cardiology, 2014, 175, 569-570.	0.8	3
105	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction. American Heart Journal, 2013, 166, 760-767.	1.2	45
106	Clinical and neurohormonal correlates and prognostic value of serum prolactin levels in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 1122-1130.	2.9	23
107	Heart Failure 2013. Cardiology Research and Practice, 2013, 2013, 1-2.	0.5	2
108	Intravenous ferric carboxymaltose in ironâ€deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIRâ€HF trial. European Journal of Heart Failure, 2013, 15, 1267-1276.	2.9	130

#	Article	IF	CITATIONS
109	Clinical profile and therapeutic management of patients with atrial fibrillation in Greece: results from the Registry of Atrial Fibrillation to Investigate New Guidelines (RAFTING). Hellenic Journal of Cardiology, 2013, 54, 368-75.	0.4	4
110	Echocardiographic Evaluation of Pulmonary Artery Pressure in Patients With Heart Failure. Journal of the American College of Cardiology, 2012, 60, 83.	1.2	1
111	High-Sensitivity Troponin Assays. Journal of the American College of Cardiology, 2012, 60, 166.	1.2	8
112	Clinical Characteristics and Predictors of In-Hospital Mortality in Acute Heart Failure With Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2011, 107, 79-84.	0.7	38
113	Pulmonary Hypertension Associated With Hemoglobinopathies. Circulation, 2011, 123, 1227-1232.	1.6	85
114	Iron Overload Cardiomyopathy in Clinical Practice. Circulation, 2011, 124, 2253-2263.	1.6	240
115	β-Thalassemia Cardiomyopathy. Circulation: Heart Failure, 2010, 3, 451-458.	1.6	171
116	Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure. International Journal of Cardiology, 2010, 139, 75-79.	0.8	23
117	Selfâ€assessment of health status is associated with inflammatory activation and predicts longâ€ŧerm outcomes in chronic heart failure. European Journal of Heart Failure, 2009, 11, 163-169.	2.9	51
118	The prognostic role of echocardiographic indices in chronic heart failure: right ventricle revisited. European Journal of Heart Failure, 2009, 11, 1220-1220.	2.9	2
119	Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study. European Journal of Heart Failure, 2009, 11, 967-972.	2.9	33
120	Hyponatremia in heart failure. Heart Failure Reviews, 2009, 14, 59-63.	1.7	54
121	Cardiac involvement in sickle β-thalassemia. Annals of Hematology, 2009, 88, 557-564.	0.8	17
122	Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis, 2008, 197, 278-282.	0.4	70
123	Treadmill exercise test with dual isotope scintigraphy documents the second window of preconditioning in humans. Atherosclerosis, 2008, 198, 122-128.	0.4	8
124	Anticoagulants, Antiplatelets, and Statins in Heart Failure. Cardiology Clinics, 2008, 26, 49-58.	0.9	12
125	Effects of functional electrical stimulation on quality of life and emotional stress in patients with chronic heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy: A randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2008, 10, 709-713.	2.9	38
126	Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica, 2007, 92, 658-665.	1.7	96

#	Article	IF	CITATIONS
127	Plasma B-type natriuretic peptide concentration in β-thalassaemia patients. European Journal of Heart Failure, 2007, 9, 537-541.	2.9	12
128	Endothelial function and arterial stiffness in sickle-thalassemia patients. Atherosclerosis, 2007, 191, 427-432.	0.4	61
129	Levosimendan for the Treatment of Acute Heart Failure Syndromes: Time to Identify Subpopulations of Responding Patients. American Journal of Cardiology, 2007, 99, 146-147.	0.7	14
130	Intensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamine. International Journal of Hematology, 2007, 86, 212-215.	0.7	20
131	Classical inotropes and new cardiac enhancers. Heart Failure Reviews, 2007, 12, 149-156.	1.7	79
132	Functional electrical stimulation improves endothelial function and reduces peripheral immune responses in patients with chronic heart failure. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 592-597.	3.1	70
133	Aortic Valve Replacement in a Patient With Thalassemia Intermedia. Annals of Thoracic Surgery, 2006, 81, 737-739.	0.7	14
134	Effects of Levosimendan Versus Dobutamine on Inflammatory and Apoptotic Pathways in Acutely Decompensated Chronic Heart Failure. American Journal of Cardiology, 2006, 98, 102-106.	0.7	117
135	Effects of Levosimendan on Right Ventricular Function in Patients With Advanced Heart Failure. American Journal of Cardiology, 2006, 98, 1489-1492.	0.7	103
136	Effects of Levosimendan on Markers of Left Ventricular Diastolic Function and Neurohormonal Activation in Patients With Advanced Heart Failure. American Journal of Cardiology, 2005, 96, 423-426.	0.7	94
137	Myelodysplastic syndrome associated with multiple autoimmune disorders. Clinical Rheumatology, 2005, 24, 428-430.	1.0	7
138	Levosimendan for the treatment of acute heart failure syndromes. Expert Opinion on Pharmacotherapy, 2005, 6, 2741-2751.	0.9	36
139	Thalassemia Heart Disease. Chest, 2005, 127, 1523-1530.	0.4	192
140	Visual loss associated with angioid streaks in sickle thalassemia. Haematologica, 2005, 90, ECR02.	1.7	2
141	Comments on the European guidelines on cardiovascular disease prevention. European Heart Journal, 2004, 25, 619.	1.0	2
142	Rupture of chordae tendineae in patients with β-thalassemia. European Journal of Haematology, 2004, 72, 296-298.	1.1	7
143	Cardiac status in well-treated patients with thalassemia major. European Journal of Haematology, 2004, 73, 359-366.	1.1	150
144	Aneurysmatic dilatation of ascending aorta in a patient with ?-thalassemia and a pseudoxanthoma elasticum-like syndrome. Annals of Hematology, 2004, 83, 596-9.	0.8	21

#	Article	IF	CITATIONS
145	Unstable angina associated with coronary arterial calcification in a thalassemia intermedia patient with a pseudoxanthoma elasticumâ€like syndrome. European Journal of Haematology, 2003, 70, 64-66.	1.1	16
146	Unstable angina associated with coronary arterial calcification in a thalassemia intermedia patient with a pseudoxanthoma elasticum-like syndrome. , 2003, 70, 64.		5
147	Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Medical Science Monitor, 2003, 9, RA19-22.	0.5	57
148	Unstable angina associated with coronary arterial calcification in a thalassemia intermedia patient with a pseudoxanthoma elasticum-like syndrome. European Journal of Haematology, 2003, 70, 64-6.	1.1	5
149	Elastic tissue abnormalities resembling pseudoxanthoma elasticum in β thalassemia and the sickling syndromes. Blood, 2002, 99, 30-35.	0.6	136
150	Exercise-induced myocardial perfusion abnormalities in sickle β-thalassemia: Tc-99m tetrofosmin gated SPECT imaging study. American Journal of Medicine, 2001, 111, 355-360.	0.6	18
151	Cardiac involvement in thalassemia intermedia: a multicenter study. Blood, 2001, 97, 3411-3416.	0.6	254
152	Doppler-Determined Peak Systolic Tricuspid Pressure Gradient in Persons with Normal Pulmonary Function and Tricuspid Regurgitation. Journal of the American Society of Echocardiography, 2000, 13, 645-649.	1.2	41
153	Pseudoxanthoma Elasticum Lesions and Cardiac Complications as Contributing Factors for Strokes in β-Thalassemia Patients. Stroke, 1997, 28, 2421-2424.	1.0	46